Edited by
VAL R. ADAMS
THOMAS G. BURKE

2005

Clinical interest in the camptothecins continues to expand despite the fact that this class of agents has been studied for almost 50 years and two early generation members of the family have gained FDA approval. To date, the intensive research efforts carried have clearly validated the utility of this class of topoisomerase I inhibitor in the management of human cancer.